Trial Profile
A retrospective trial evaluated the safety and efficacy of Pemetrexed (Alimta) in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2016
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2016 New trial record